{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:21:45Z","timestamp":1794392505372,"version":"4.9.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T00:00:00Z","timestamp":1317254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Viral Immunology"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>\n                    Widespread vaccination with vaccinia virus (VACV) resulted in the eradication of smallpox; however, the licensed VACV-containing vaccines are associated with adverse events (AEs), making them unsuitable for certain high-risk populations. A better understanding of the host immune response following smallpox vaccination could result in vaccines with similar immunogenicity profiles to pre-eradication vaccines with a lower incidence of AEs. To study the immune response to VACV, we recruited 1,076 armed forces members who had been vaccinated with one dose of Dryvax\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . We measured multiple VACV-specific immune responses: neutralizing antibody titer, the level of 12 secreted cytokines in peripheral blood mononuclear cell (PBMC) cultures (IL-1\u03b2, IL-2, IL-4, IL-6, IL-10, IL-12p40, IL-12p70, TNF-\u03b1, IFN-\u03b3, IFN-\u03b1, IFN-\u03b2, and IL-18), and the number of IFN-\u03b3- and CD8\n                    <jats:sup>+<\/jats:sup>\n                    IFN-\u03b3-secreting cells. We analyzed these data to determine correlations between immune response measures. We detected a strong proinflammatory response in concert with a Th-1-like cytokine response pattern at a median time point of 15.3\u2009mo following primary vaccination. We also detected correlations between neutralizing antibody titer and secreted IL-2, as well as secreted IFN-\u03b3 (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.009 and\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.0007, respectively). We also detected strong correlations between the proinflammatory cytokines IL-1\u03b2, TNF-\u03b1, IL-6, and IL-12p40 (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.0001). These results further advance our knowledge of vaccinia-specific cellular immune responses. Notably, vaccine-induced proinflammatory responses were not correlated with neutralizing antibody titers, suggesting that further attenuation to reduce inflammatory immune responses may result in decreased AEs without sacrificing VACV immunogenicity and population seropositivity.\n                  <\/jats:p>","DOI":"10.1089\/vim.2011.0029","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T16:05:29Z","timestamp":1317312329000},"page":"415-420","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Correlations Between Vaccinia-Specific Immune Responses Within a Cohort of Armed Forces Members"],"prefix":"10.1177","volume":"24","author":[{"given":"Benjamin J.","family":"Umlauf","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna G.","family":"Ovsyannikova","sequence":"additional","affiliation":[{"name":"Mayo Clinic"},{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana H.","family":"Haralambieva","sequence":"additional","affiliation":[{"name":"Mayo Clinic"},{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Mayo Clinic"},{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Vierkant","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Shane","family":"Pankratz","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Mayo Clinic"},{"name":"Mayo Clinic"},{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[{"name":"Mayo Clinic"},{"name":"Mayo Clinic"},{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,9,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21621"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.4.5751"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/380906"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.6336"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/651453"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0306190"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02931.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/09680519040100040301"},{"key":"e_1_3_3_10_2","article-title":"Generation of recombinant vaccinia viruses","volume":"16","author":"Earl PL","year":"2001","unstructured":"Earl PL, , Moss B, , Wyatt LS, , Carroll MW. Generation of recombinant vaccinia viruses. Curr Protoc Mol Biol, 2001; Chap 16:Unit 16.","journal-title":"Curr Protoc Mol Biol"},{"key":"e_1_3_3_11_2","article-title":"Preparation of cell cultures and vaccinia virus stocks","volume":"16","author":"Earl PL","year":"2001","unstructured":"Earl PL, , Cooper N, , Wyatt LS, , Moss B, , Carroll MW. Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Mol Biol, 2001; Chap 16:Unit 16.","journal-title":"Curr Protoc Mol Biol"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.029"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.079"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.10.045"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.4.431.32127"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00109-09"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.103"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.04.004"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.086"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/376557"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/505503"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.06.002"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-004-0756-0"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90223-Y"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/382510"},{"key":"e_1_3_3_26_2","first-page":"1","article-title":"Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001","volume":"50","author":"Rotz LD","year":"2001","unstructured":"Rotz LD, , Dotson DA, , Damon IK, , Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep, 2001; 50:1\u201325.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.11.001"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365510500348252"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2009.0068"},{"key":"e_1_3_3_30_2","article-title":"Detection of vaccinia virus-specific IFN-g and IL-10 secretion from human PBMC and CD8+ T cells by ELISPOT","author":"Umlauf BJ","year":"2011","unstructured":"Umlauf BJ, , Pinsky NA, , Ovsyannikova IG, , Poland GA. Detection of vaccinia virus-specific IFN-g and IL-10 secretion from human PBMC and CD8+ T cells by ELISPOT. Methods in Molecular Biology, 2011(In press).","journal-title":"Methods in Molecular Biology"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3534"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.022"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6265"}],"container-title":["Viral Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/vim.2011.0029","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vim.2011.0029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vim.2011.0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T09:30:18Z","timestamp":1794389418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/vim.2011.0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,29]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1089\/vim.2011.0029"],"URL":"https:\/\/doi.org\/10.1089\/vim.2011.0029","relation":{},"ISSN":["0882-8245","1557-8976"],"issn-type":[{"value":"0882-8245","type":"print"},{"value":"1557-8976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,29]]}}}